User login
MILAN – Dr. Andrew W. Roberts discusses the high response rates that have occurred with the Bcl-2 inhibitor ABT-199, alone and in combination, against refractory or relapsed chronic lymphocytic leukemia.
Drug-induced tumor lysis syndrome in some patients appears to have been avoided with a new modified dosing regimen, said Dr. Roberts, who presented phase Ib study results of ABT-199 in combination with rituximab at the annual congress of the European Hematology Association. In the interview, Dr. Roberts of the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, describes the study results and future plans for ABT-199 research.
lnikolaides@frontlinemedcom.com
On Twitter @nikolaideslaura
MILAN – Dr. Andrew W. Roberts discusses the high response rates that have occurred with the Bcl-2 inhibitor ABT-199, alone and in combination, against refractory or relapsed chronic lymphocytic leukemia.
Drug-induced tumor lysis syndrome in some patients appears to have been avoided with a new modified dosing regimen, said Dr. Roberts, who presented phase Ib study results of ABT-199 in combination with rituximab at the annual congress of the European Hematology Association. In the interview, Dr. Roberts of the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, describes the study results and future plans for ABT-199 research.
lnikolaides@frontlinemedcom.com
On Twitter @nikolaideslaura
MILAN – Dr. Andrew W. Roberts discusses the high response rates that have occurred with the Bcl-2 inhibitor ABT-199, alone and in combination, against refractory or relapsed chronic lymphocytic leukemia.
Drug-induced tumor lysis syndrome in some patients appears to have been avoided with a new modified dosing regimen, said Dr. Roberts, who presented phase Ib study results of ABT-199 in combination with rituximab at the annual congress of the European Hematology Association. In the interview, Dr. Roberts of the Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, describes the study results and future plans for ABT-199 research.
lnikolaides@frontlinemedcom.com
On Twitter @nikolaideslaura
AT THE EHA CONGRESS
